Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the effect of various mood stabilizers (MS) on
the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in
patients treated with antipsychotic drugs (APDs). Patients will be switched from their
current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless
clinically contraindicated) for comparison with metabolic levels during treatment with the
former medication.
The metabolic syndrome is an empirical concept based on extensive evidence that a
constellation of 5 metabolic abnormalities, e.g. increased cholesterol, hypertension, low
HDL, taken together, predict marked increases in the risk of CVD, stroke and some types of
cancer.
Phase:
N/A
Details
Lead Sponsor:
Northwestern University Vanderbilt University Medical Center
Collaborators:
National Alliance for Research on Schizophrenia and Depression Pfizer